News Column

Plandai Primed to Fight Colon Cancer

Jul 9 2013 12:00AM

Marketwire

Tracker

BALTIMORE, MD -- (Marketwired) -- 07/09/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that due to the high absorption rates in its flagship offerings, Plandai Biotechnology Inc. (OTCQB: PLPL) may soon enter the colon cancer fighting arena.

The American Cancer Society estimates that this year 142,820 people will be diagnosed with and 50,830 will die from colon cancer in the U.S. The disease is the third most commonly diagnosed cancer and the second leading cause of cancer death in the U.S. Still, studies have shown that certain substances and nutrients may be beneficial to fighting colon cancer.

For example, carotenoids are substances found in fruits that give them their respective bright colors, such as tomatoes and oranges. In published studies, carotenoids have demonstrated an ability to provide nutrients beneficial in fighting colon cancer. For example, Lutein, a compound that is found in 600 or so naturally-occurring carotenoids, has been shown to have the greatest effect in the fight. Data from several American Journal of Medicine studies have shown that subjects who incorporated meaningful quantities of carotenoid and lutein foods into their diet such as spinach, broccoli, lettuce, tomatoes, oranges, carrots, and celery have been clearly aided in reducing their risk of developing colon cancer.

Plandai's Phytofare Carotenoid Botanical Extract is a unique product that harnesses the beneficial effects of these nutrients due to Plandai's unique and advanced extraction process and absorption into the circulatory system which enables absorption and bioavailability many times greater than other extraction and delivery systems. Therefore, this extract could potentially emerge as the carotenoid extract of choice for manufacturers in the nutraceutical and foods arenas.

As part of Plandai's objective of producing and marketing highly bioavailable ingredients that have proven benefits to immune health and the prevention of diseases and conditions, the Company plans to market this product sometime in 2014. This is good news not just for the health conscious consumer, but for those actively seeking to use products that offer the greatest absorption rate in their quest to prevent the onset of disease and cancer.

Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.






Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com





Source: Marketwire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters